Prevention of ventilator associated pneumonia (VAP)

Abstract

Ventilator associated pneumonia (VAP) may be prevented in a patient, or its occurrence reduced in a population of patients, by using an anti-VAP device or an anti-VAP material. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of the intubated patient, VAP can be prevented from occurring in intubated patients, such as patients intubated with an endotracheal tube (ETT) or a nasogastric tube.

Description

RELATED APPLICATION [0001] This application claims benefit of U.S. provisional application No. 60 / 607,070 filed Sep. 3, 2004 titled “Device and methods to prevent ventilator associated pneumonia and to provide laryngeal anesthesia during mechanical ventilation.”FIELD OF THE INVENTION [0002] This invention relates to treatment of patients who are intubated with an endotracheal tube (ETT), and especially to ventilator associated pneumonia (VAP) undesirably associated with such intubation. BACKGROUND OF THE INVENTION [0003] Ventilator associated pneumonia (VAP) is a potentially preventable cause of pneumomia that occurs in patients who are endotracheally intubated and mechanically ventilated for more than 48 hours. VAP may occur in up to 65% of patients in the intensive care unit (ICU) and is associated with an increase in morbidity and mortality. It is estimated that cost of diagnosing and treating VAP exceeds 1.1 billion dollars annually. Young P J, Ridley S A, Ventilator-associated ...

AI Technical Summary

Benefits of technology

[0019] The above problems and shortcomings have been addressed by the present invention. The present inventors have recognized that ventilator associated pneumonia (VAP) may be prevented in a patient (such as, e.g., a human patient, a veterinary patient), or its occurrence reduced in a population of patients, by using a relatively-simple anti-VAP device or an anti-VAP material in a space that otherwise would be where bacterial-containing secretions would form. By reducing the problem of bacterial-containing secretions that otherwise build up in the airway of the intubated patient, VAP can be prevented from occurring in intubated patients.

[0022] The invention in another preferred embodiment provides a method of reducing occurrence of ventilator associated pneumonia (VAP) in a population of patients endotracheally intubated, comprising: for each patient, disposing an anti-VAP device or an anti-VAP material in a region where secretions otherwise build up in the airway of the patient when intubated (such as disposing performed before patient intubation; disposing performed after patient intubation; disposing performed a mixture of before and after patient intubation), such as, e.g., methods comprising attaching an anti-VAP attachment to an endotracheal tube; methods wherein microaspiration is reduced; methods wherein oropharyngeal bacterial load is reduced; etc.

[0024] A further preferred embodiment of the invention provides a method of reducing or preventing colonization of the respiratory tract with gastrointestinal organisms, such as by, e.g., a device or material that partially recedes into the upper esophagus, whereby colonization of the respiratory tract with gastrointestinal organisms is reduced or prevented; etc.

[0027] Another preferred embodiment of the invention provides a method of reducing occurrence of ventilator associated pneumonia (VAP) in a patient whose esophagus is intubated with a nasogastric tube, comprising: disposing an anti-VAP device or an anti-VAP material in a region where secretions otherwise build up in the airway of the patient when intubated with the nasogastric tube and where these secretions may come from the esophagus.

Problems solved by technology

VAP may occur in up to 65% of patients in the intensive care unit (ICU) and is associated with an increase in morbidity and mortality.

It is estimated that cost of diagnosing and treating VAP exceeds 1.1 billion dollars annually.

The diagnosis of VAP is difficult and expensive.

Controversy continues to exists in the methodology in making a definitive diagnosis.

Treatment is also controversial and the use of empiric antibiotics is believed to have contributed to making the overall treatment of true VAP more difficult.

A major cost to the treatment is prolonging the time patients require mechanical ventilation and thus care in the ICU setting.

This increased time of treatment in this setting is likely to actually increase the chances of additional complications including developing additional VAPs and antibiotic resistant organisms.

However, higher volumes will result in higher pressures being created between the cuff and the tracheal mucosa thus placing the tracheal mucosa at risk for necrosis.

The disadvantage of this method is that suction is required.

Because endotracheal intubation occurs in many non-ICU areas, suction is not readily available.

Patients are likely to be a most risk for aspiration from subglottic secretions very early after intubation especially when it is performed in less than ideal places such as on the wards, the emergency department, or in the prehospital setting.

A number of methods, which involve changes in cuff design, have reported various degrees of success but none have undergone extensive clinical testing.

In regards to this, intubation done in less than ideal circumstances where patients may be at greatest risk for microaspiration means that antibiotic embedded systems or tubes designed to prevent formation of biofilm might not be effective in this time early time range.

Another major problem in the patient requiring endotracheal intubation and mechanical ventilation is the need for sedation due to the coughing reflexes induced by contact of the endotracheal tube and cuff with points of the supra and subglottic portions of the larynx.

This degree of additional sedation can impede physical and neurologic assessment of the patient and delay efforts for weaning of mechanical ventilation.

This is of great importance because additional time spent utilizing mechanical ventilation will necessarily result in the incurrence of significant expense and may potentially result in the development of VAP with all of its complications and additional expense.

Conventional strategies to reduce VAP necessitate purchase of a separate endotracheal tube, which making implementation difficult especially if VAP prevention strategies are to be performed in all settings at the earliest possible time.

In addition, each conventional strategy is relatively singular or limited in its ability to prevent VAP.

Images